Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 18c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.59), $0.18 better than the analyst estimate of ($0.77).

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Morgan Stanley continues to recommend exposure to the broadening theme
• Strategy stock jumps 7% as firm shifts to active capital management
• ByteDance looks to finalize in-house CPU design, seeks to power its own infrastructure - SCMP